Please use this identifier to cite or link to this item:
|Title:||Optimizing the treatment regimen for targeted alpha therapy of mCRPC with 225Ac-PSMA-617|
|Authors:||KRATOCHWIL CLEMENS; RATHKE H; BRUCHERTSEIFER FRANK; GIESEL FREDERIK; HABERKORN UWE; MORGENSTERN ALFRED|
|Citation:||EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING vol. 45 no. S1 p. S54|
|Type:||Articles in periodicals and books|
|Abstract:||PSMA-targeting alpha-therapy (PSMA-TAT) of mCRPC with 225Ac-PSMA-617 (8 MBq, 3 cycles, 8 week intervals) already demonstrated promising anti-tumor activity, but also induced severe and often irreversible xerostomia (1,2). Our objective was to optimize the treatment protocol to improve tolerability.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.